A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.

PHASE3CompletedINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Liver Transplantation
Interventions
DRUG

tacrolimus

immunosuppression

Trial Locations (51)

2050

Sydney

4000

Liège

9000

Ghent

21041

Rio de Janeiro

30130

Bel Horizonte

VIC 3084

Heidelberg

Unknown

Porto Alegre

Edmonton

Vancouver

London

Toronto

Montreal

Prague

Helsinki

Clichy

Créteil

Lyon

Montpellier

Rennes

Strasbourg

Toulouse

Villejuif

Berlin

Hamburg

Heidelberg

Regensburg

Dublin

Bergamo

Bologna

Genova

Modena

Palermo

Udine

Oslo

Warsaw

Barakaldo

Córdoba

Santiago de Compostela

Seville

Valencia

Gothenburg

Stockholm

Bern

Zurich

Leeds

Newcastle upon Tyne

01431

São Paulo

08035

Barcelona

08036

Barcelona

NW3 2QG

London

SE5 9 RS

London

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY